UPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES
|
|
|
- Jesse Ray
- 5 years ago
- Views:
Transcription
1 UPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Off Formulary Interchangeable Product(s) 5 Change(s) to Strength and Dosage Form 6 Drug Benefit Price(s) 7 New Manufacturer Name(s) 9 Therapeutic Note Change(s) 10 Palliative Care Drug(s) 11 ReInstated Drug(s) (Added to Payment) 12 Status Change(s) from Not-A-Benefit to General Benefit 13 Status Change(s) from Discontinued Drug(s) to Not-A-Benefit 14 Trade Name Change(s) 15 Index 16 Page 1
2 New Multi-Source Drug(s) DIN BRAND STRENGTH DOSAGE FORM MFR DBP It is recommended that Pharmacists inform their patients when a different brand of imatinib is dispensed to support appropriate monitoring. In patients with CML, regular response monitoring is recommended, particularly when therapy is modified, to detect any changes in response so that actions may be implemented as appropriate Apo-Imatinib 100mg Tab APX Apo-Imatinib 400mg Tab APX (Interchangeable with Gleevec) These products must be prescribed based on the following criteria: 1) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in chronic phase. The initial dose is 400mg/day. The dose may be increased up to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response. Note: The Ministry will only reimburse, in a patient's lifetime, any two (2) of the oral Tyrosine Kinase Inhibitors (TKIs)* used for chronic phase CML. (* TKIs: Imatinib, Nilotinib, or Dasatinib ) 2) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in blast phase or accelerated phase. The initial dose is 600mg/day. The dose may be increased to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response Auro-Losartan 25mg Tab AUR Auro-Losartan 50mg Tab AUR Auro-Losartan (Interchangeable with Cozaar) 100mg Tab AUR Page 2
3 DIN BRAND STRENGTH DOSAGE FORM MFR DBP Co Temozolomide 20mg Cap COB Co Temozolomide 100mg Cap COB Co Temozolomide 140mg Cap COB Co Temozolomide 250mg Cap COB (Interchangeable with Temodal) Reason for Use Code Clinical Criteria 320 For patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma. LU Authorization Period: Indefinite. 425 For the treatment of newly diagnosed glioblastoma multiforme. Dose: Temozolomide 75 milligrams per square metre daily for up to 6 weeks concomitant with radiotherapy, followed by maintenance treatment of up to 200 milligrams per square metre daily for 5 days for 6 cycles. LU Authorization Period: 1 year Freya mg & 0.03mg Tab-21 Pk FAM Freya mg & 0.03mg Tab-28 Pk FAM (Interchangeable with Marvelon) Jamp-Alprazolam 0.25mg Tab JPC Jamp-Alprazolam 0.5mg Tab JPC (Interchangeable with Xanax) Jamp-Losartan 25mg Tab JPC Jamp-Losartan 50mg Tab JPC Jamp-Losartan (Interchangeable with Cozaar) 100mg Tab JPC Page 3
4 DIN BRAND STRENGTH DOSAGE FORM MFR DBP Mylan-Fentanyl Matrix Patch 25mcg/hr Trans Patch MYL Mylan-Fentanyl Matrix Patch 50mcg/hr Trans Patch MYL Mylan-Fentanyl Matrix Patch 75mcg/hr Trans Patch MYL Mylan-Fentanyl Matrix Patch 100mcg/hr Trans Patch MYL (Interchangeable with Duragesic) Reason for Use Code Clinical Criteria 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. LU Authorization Period: 1 Year Sandoz Fluvastatin 20mg Cap SDZ Sandoz Fluvastatin 40mg Cap SDZ (Interchangeable with Lescol) It is recommended that Pharmacists inform their patients when a different brand of imatinib is dispensed to support appropriate monitoring. In patients with CML, regular response monitoring is recommended, particularly when therapy is modified, to detect any changes in response so that actions may be implemented as appropriate Teva-Imatinib 100mg Tab TEV Teva-Imatinib 400mg Tab TEV (Interchangeable with Gleevec) These products must be prescribed based on the following criteria: 1) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in chronic phase. The initial dose is 400mg/day. The dose may be increased up to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response. Note: The Ministry will only reimburse, in a patient's lifetime, any two (2) of the oral Tyrosine Kinase Inhibitors (TKIs)* used for chronic phase CML. (* TKIs: Imatinib, Nilotinib, or Dasatinib ) 2) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in blast phase or accelerated phase. The initial dose is 600mg/day. The dose may be increased to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response. Page 4
5 Off Formulary Interchangeable Product(s) DIN BRAND STRENGTH DOSAGE FORM MFR UNIT COST Apo-Eletriptan 20mg Tab APX Apo-Eletriptan 40mg Tab APX (Interchangeable with Relpax) Midazolam Injection (Interchangeable with Versed) 5mg/mL Inj Sol-2mL Vial Pk PPC Mylan-Fentanyl Matrix Patch (Interchangeable with Duragesic) 12mcg/hr Trans Patch MYL Novo-Glimepiride 2mg Tab NOP Novo-Glimepiride 4mg Tab NOP (Interchangeable with Amaryl) Pilocarpine Hydrochloride Tablets USP (Interchangeable with Salagen Tablets) 5mg Tab STE Teva-Nabilone (Interchangeable with Cesamet) 0.25mg Cap TEV Page 5
6 Change(s) to Strength and Dosage Form DIN BRAND STRENGTH DOSAGE FORM MFR R & C Shampoo/Conditioner 0.33% & 3% Topical Shampoo GSK PYRETHRINS 0.33% & PIPERONYL BUTOXIDE 3% Page 6
7 Drug Benefit Price(s) DIN BRAND STRENGTH DOSAGE FORM MFR DBP Androderm 12.2mg Transdermal Patch WAT Apo-Bromazepam 1.5mg Tab APX Apo-Flunisolide 0.025% Nas Sp-25mL Pk APX Apo-Ibuprofen 200mg Tab APX Apo-Pen V-K 300mg Tab APX Apo-Prednisone 50mg Tab APX BenzaClin 1% & 5% Top Gel SAV C.E.S mg Tab VAL Carbolith 150mg Cap VAL Carbolith 300mg Cap VAL Cardizem CD 120mg LA Cap BIO Cardizem CD 180mg LA Cap BIO Cardizem CD 240mg LA Cap BIO Cardizem CD 300mg LA Cap BIO Cesamet 0.5mg Cap VAL Cesamet 1mg Cap VAL Cuprimine 250mg Cap ATO Delatestryl 1000mg/5mL Oily Inj Sol-5mL Pk THE Diastat 5mg/mL Rect Gel-2x 5mg Pk VAL Diastat 5mg/mL Rect Gel-2x10mg Pk VAL Diastat 5mg/mL Rect Gel-2x15mg Pk VAL Efudex 5% Cr VAL Etibi 100mg Tab VAL Etibi 400mg Tab VAL Hycort 100mg/60mL Enema-60mL Pk VAL M-Eslon 10mg ER Cap ETH M-Eslon 15mg ER Cap ETH M-Eslon 30mg ER Cap ETH M-Eslon 60mg ER Cap ETH M-Eslon 100mg ER Cap ETH M-Eslon 200mg ER Cap ETH Manerix 150mg Tab HLR Manerix 300mg Tab HLR Mestinon 60mg Tab VAL Mestinon 180mg LA Tab VAL Mogadon 5mg Tab VAL Mogadon 10mg Tab VAL Niacin-ICN 100mg Tab VAL Noritate 1% Top Cr SAV Portia mg & 0.15mg Tab-21 Pk APX Portia mg & 0.15mg Tab-28 Pk APX Prostigmin 15mg Tab VAL Rapaflo 4mg Cap WAT Rapaflo 8mg Cap WAT Rofact 150mg Cap VAL Page 7
8 DIN BRAND STRENGTH DOSAGE FORM MFR DBP Rofact 300mg Cap VAL Tiazac 120mg SR Cap BIO Tiazac 180mg SR Cap BIO Tiazac 240mg SR Cap BIO Tiazac 300mg SR Cap BIO Tiazac 360mg SR Cap BIO Tiazac XC 120mg ER Tab BIO Tiazac XC 180mg ER Tab BIO Tiazac XC 240mg ER Tab BIO Tiazac XC 300mg ER Tab BIO Tiazac XC 360mg ER Tab BIO Viroptic 1% Oph Sol THE Vitamin A Acid 0.01% Gel SAV Vitamin A Acid 0.05% Gel SAV Wellbutrin SR 150mg Tab BIO Wellbutrin XL 150mg Tab BIO Wellbutrin XL 300mg Tab BIO Winpred 1mg Tab VAL Zyban 150mg SR Tab VAL Page 8
9 New Manufacturer Name(s) DIN BRAND STRENGTH DOSAGE FORM MFR Apo-Bromocriptine 2.5mg Cap AAP Apo-Bromocriptine 5mg Cap AAP Apo-Hydralazine 10mg Tab AAP Apo-Hydralazine 25mg Tab AAP Apo-Hydralazine 50mg Tab AAP Apo-Methoprazine 2mg Tab AAP Apo-Methoprazine 5mg Tab AAP Apo-Methoprazine 25mg Tab AAP Apo-Methoprazine 50mg Tab AAP Kwellada-P 1% Cr Rinse MEP Kwellada-P 5% Lot MEP Manerix 150mg Tab MAB Manerix 300mg Tab MAB Methotrexate 2.5mg Tab PFI Noritate 1% Top Cr VAL Novo-Lamotrigine 25mg Tab TEV Novo-Lamotrigine 100mg Tab TEV Novo-Lamotrigine 150mg Tab TEV Novo-Pramipexole 0.25mg Tab TEV Novo-Pramipexole 0.5mg Tab TEV Novo-Pramipexole 1mg Tab TEV Novo-Pramipexole 1.5mg Tab TEV R & C Shampoo/Conditioner 0.33% & 3% Topical Shampoo MEP Vitamin A Acid 0.01% Gel VAL Vitamin A Acid 0.05% Gel VAL Wellbutrin SR 150mg Tab VAL Page 9
10 Therapeutic Note Change(s) DIN BRAND STRENGTH DOSAGE FORM MFR It is recommended that Pharmacists inform their patients when a different brand of imatinib is dispensed to support appropriate monitoring. In patients with CML, regular response monitoring is recommended, particularly when therapy is modified, to detect any changes in response so that actions may be implemented as appropriate Gleevec 100mg Tab NOV Gleevec 400mg Tab NOV These products must be prescribed based on the following criteria: 1) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in chronic phase. The initial dose is 400mg/day. The dose may be increased up to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response. Note: The Ministry will only reimburse, in a patient's lifetime, any two (2) of the oral Tyrosine Kinase Inhibitors (TKIs)* used for chronic phase CML. (* TKIs: Imatinib, Nilotinib, or Dasatinib ) 2) For the treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in blast phase or accelerated phase. The initial dose is 600mg/day. The dose may be increased to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response. Page 10
11 Palliative Care Drug(s) DIN BRAND STRENGTH DOSAGE FORM MFR Midazolam Injection 5mg/mL Inj Sol-2mL Vial Pk PPC Page 11
12 ReInstated Drug(S) (Added To Payment) DIN BRAND STRENGTH DOSAGE FORM MFR DBP Novo-Metformin 500mg Tab NOP Page 12
13 Status Change(s) from Not-A-Benefit to General Benefit DIN BRAND STRENGTH DOSAGE FORM MFR DBP Co Pregabalin 25mg Cap COB Co Pregabalin 50mg Cap COB Co Pregabalin 75mg Cap COB Co Pregabalin 150mg Cap COB Co Pregabalin 300mg Cap COB (Interchangeable with Lyrica) PMS-Pregabalin 25mg Cap PMS PMS-Pregabalin 50mg Cap PMS PMS-Pregabalin 75mg Cap PMS PMS-Pregabalin 150mg Cap PMS PMS-Pregabalin 300mg Cap PMS (Interchangeable with Lyrica) Sandoz Pregabalin 25mg Cap SDZ Sandoz Pregabalin 50mg Cap SDZ Sandoz Pregabalin 75mg Cap SDZ Sandoz Pregabalin 150mg Cap SDZ Sandoz Pregabalin 300mg Cap SDZ (Interchangeable with Lyrica) Teva-Quetiapine XR 50mg ER Tab TEV Teva-Quetiapine XR 150mg ER Tab TEV Teva-Quetiapine XR 200mg ER Tab TEV Teva-Quetiapine XR 300mg ER Tab TEV Teva-Quetiapine XR 400mg ER Tab TEV (Interchangeable with Seroquel XR) Page 13
14 Status Change(s) from Discontinue Drug(s) to Not-A-Benefit DIN BRAND STRENGTH DOSAGE FORM MFR PMS-Benzydamine 0.15% Oral Rinse PMS Page 14
15 Trade Name Change(s) DIN BRAND STRENGTH DOSAGE FORM MFR Biaxin BID 250mg Tab ABB Biaxin BID 500mg Tab ABB Bromocriptine 2.5mg Cap APX Bromocriptine 5mg Cap APX Hydralazine 10mg Tab APX Hydralazine 25mg Tab APX Hydralazine 50mg Tab APX Kwellada-P Creme Rinse 1% Cr Rinse GSK Kwellada-P Lotion 5% Lot GSK Methoprazine 2mg Tab APX Methoprazine 5mg Tab APX Methoprazine 25mg Tab APX Methoprazine 50mg Tab APX R & C Shampoo with Conditioner 0.33% & 3% Topical Shampoo GSK Ran-Risperidone 0.25mg Tab RAN Ran-Risperidone 0.5mg Tab RAN Ran-Risperidone 1mg Tab RAN Ran-Risperidone 2mg Tab RAN Ran-Risperidone 3mg Tab RAN Ran-Risperidone 4mg Tab RAN Teva-Lamotrigine 25mg Tab NOP Teva-Lamotrigine 100mg Tab NOP Teva-Lamotrigine 150mg Tab NOP Teva-Pramipexole 0.25mg Tab NOP Teva-Pramipexole 0.5mg Tab NOP Teva-Pramipexole 1mg Tab NOP Teva-Pramipexole 1.5mg Tab NOP Page 15
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes August 2018 Effective August 30, 2018 Drug Programs Policy and Strategy Branch
UPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES
UPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Off Formulary Interchangeable Product(s)
UPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES
UPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Off
UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES
UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 4 Off Formulary
Ontario Drug Benefit Formulary/ Comparative Drug Index
Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes December 2013 Effective January 03, 2014 Ministry of Health and Long-Term Care Table of Contents Additions to Formulary...
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes June 2017 Effective June 29, 2017 Drug Programs Policy and Strategy Branch Ontario
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes September 2017 Effective September 28, 2017 Drug Programs Policy and Strategy Branch
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes July 2016 Effective July 28, 2016 Drug Programs Policy and Strategy Branch Ontario
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - February 2015 Effective February 26, 2015 Ministry of Health and Long-Term Care Table of Contents New Multi-Source
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - December 2014 Effective December 18, 2014 Ministry of Health and Long-Term Care Table of Contents New Multi-Source
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes December 2016 Effective December 22, 2016 Drug Programs Policy and Strategy Branch
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes June 2018 Effective June 29, 2018 Drug Programs Policy and Strategy Branch Ontario
Ontario Drug Benefit Formulary/ Comparative Drug Index
Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes March 2014 Effective March 27, 2014 Ministry of Health and Long-Term Care Table of Contents Additions to Formulary...
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes July 2017 Effective July 31, 2017 Drug Programs Policy and Strategy Branch Ontario
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - November 2014 Effective November 27, 2014 Ministry of Health and Long-Term Care Table of Contents New Single Source
UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES
UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes December 2018 Effective December 21, 2018 Drug Programs Policy and Strategy Branch
UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES
UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes October 2017 Effective October 30, 2017 Drug Programs Policy and Strategy Branch
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - July 2014 Effective July 30, 2014 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
UPDATE E Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective December 23, 2008 SUMMARY OF CHANGES
UPDATE E Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective December 23, 2008 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 New Drug Identification Number(s)
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes February 2019 Effective February 28, 2019 Drug Programs Policy and Strategy Branch
UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES
UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Exceptional
UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES
UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - August 2015 Effective August 26, 2015 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
UPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES
UPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Manufacturer
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes April 2018 Effective April 30, 2018 Drug Programs Policy and Strategy Branch Ontario
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - October 2015 Effective October 29, 2015 Drug Program Services Branch/Ontario
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes December 2017 Effective December 21, 2017 Drug Programs Policy and Strategy Branch
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes January 2018 Effective January 31, 2018 Drug Programs Policy and Strategy Branch
NB Drug Plans Formulary Update
Bulletin #973 April 30, 2018 NB Drug Plans Formulary Update Generic drug product updates included in this bulletin: Generic drug product additions - New generic products will be reimbursed up to the category
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - January 2015 Effective January 28, 2015 Ministry of Health and Long-Term Care Table of Contents New Multi-Source Products...
NB Drug Plans Formulary Update
Bulletin #915 October 30, 2015 NB Drug Formulary Update Please find attached a list of generic drug product updates for the New Brunswick Drug Formulary. Generic drug product additions New generic products
NB Drug Plans Formulary Update
Bulletin #984 October 31, 2018 NB Drug Formulary Update Drug product updates included in this bulletin: Drug product additions - New generic products will be reimbursed up to the category Maximum Allowable
UPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES
UPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Manufacturer Requested Discontinued
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes March 2019 Effective March 28, 2019 Drug Programs Policy and Strategy Branch Drugs
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - July 2015 Effective July 29, 2015 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories
PAGE 1 OF 7 Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, New Categories A Maximum Reimbursable Price (MRP) or Pharmacare Reimbursement Price (PRP) has been established for
New Exception Status Benefits
JULY 2012 Nova Scotia Formulary Updates New Exception Status Benefits Criteria Update: Xarelto Criteria Update: Sutent New Diabetic Products PRP Non-Insured Products Pharmacare Reimbursement Changes to
New Interchangeable Products Approved and Benefit Status Within the Nova Scotia Pharmacare Programs March 2016
PAGE 1 OF 6 New Interchangeable Products Approved and Benefit Status Within the Nova Scotia Pharmacare Programs March New Categories A Maximum Reimbursable Price (MRP) or Pharmacare Reimbursement Price
Manager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) Fax / Téléc : (902)
DRAFT To / Destinataire : All Retail Pharmacists and Staff From / Expéditeur : Faye Campbell Manager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) 368-6338 Fax / Téléc : (902) 368-4905 Subject
UPDATE AE Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective February 29, 2012 SUMMARY OF CHANGES
UPDATE AE Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective February 29, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 6 Off Formulary
PEI Drug Programs. Issue October, 2006
PEI Drug Programs Formulary Update Issue 06-04 October, 2006 The following changes and additions to the July 2006 edition of the PEI Drug Programs Formulary will be effective th October 16, 2006 unless
BULLETIN # 74. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 17, 2013
BULLETIN # 74 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 17, 2013 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes October 2018 Effective October 31, 2018 Drug Programs Policy and Strategy Branch
BULLETIN # 89. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 20, 2016
BULLETIN # 89 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 20, 2016 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES
UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Exceptional
BULLETIN # 73. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2013
BULLETIN # 73 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on July 17, 2013 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
NB Drug Plans Formulary Update
Bulletin # 963 December 15, 2017 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective December 15, 2017. Included in this bulletin: Special Authorization Benefit
Updates to the Alberta Drug Benefit List. Effective November 1, 2018
Updates to the Alberta Drug Benefit List Effective November 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Updates to the Alberta Drug Benefit List. Effective February 1, 2018
Updates to the Alberta Drug Benefit List Effective February 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
NBPDP Formulary Update
Bulletin # 830 April 4, 2012 NBPDP Formulary Update Please find attached lists of interchangeable product additions to the New Brunswick Prescription Drug Program Formulary and non-listed products subject
SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health November 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #126 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
Pharmacy Consultant, PEI Drug Programs Date : September 8, 2009 Tel / Tél : (902) Fax / Téléc : (902)
To / Destinataire : All Retail Pharmacists and Staff From / Expéditeur : Patrick Crawford Pharmacy Consultant, PEI Drug Programs Date : September 8, 2009 Tel / Tél : (902) 368-6711 Fax / Téléc : (902)
NB Drug Plans Formulary Update
Bulletin #960 October 31, 2017 NB Drug Formulary Update Please find attached a list of generic drug product updates for the New Brunswick Drug Formulary. Generic drug product additions New generic products
Archived Content. This content was archived on June 24, 2013.
This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after
UPDATE AG Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective April 24, 2012 SUMMARY OF CHANGES
UPDATE AG Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective April 24, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 4 Off Formulary
BULLETIN # 79. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 16, 2014
BULLETIN # 79 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 16, 2014 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Product Selection Committee / Comité de sélection des produits
New Brunswick Pharmaceutical Society and New Brunswick Department of Health Product Selection Committee / Comité de sélection des produits L Ordre des pharmaciens P.O. Box / C.P. 5100, Fredericton NB E3B
Product Selection Committee / Comité de sélection des produits
New Brunswick Pharmaceutical Society and New Brunswick Department of Health Product Selection Committee / Comité de sélection des produits L Ordre des pharmaciens P.O. Box / C.P. 5100, Fredericton NB E3B
BULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015
BULLETIN # 84 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 22, 2015 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Ontario Drug Benefit Formulary/ Comparative Drug Index
Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes January 2014 Effective January 30, 2014 Ministry of Health and Long-Term Care Table of Contents Additions to Formulary...
SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
Therapeutic Substitution Service - Proton Pump Inhibitors (PPIs)
FEBRUARY 2014 Nova Scotia Pharmacare Programs Updates Therapeutic Substitution Service - Proton Pump Inhibitors (PPIs) Prescription Adaptation Minimum Days' Supply Nova Scotia Formulary Updates Pan-Canadian
Palliative Coverage Drug Benefit Supplement
Palliative Coverage Drug Benefit Supplement Effective April 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Updates to the Alberta Drug Benefit List. Effective July 1, 2017
Updates to the Alberta Drug Benefit List Effective July 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
BULLETIN # 80. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 19, 2015
BULLETIN # 80 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on January 19, 2015 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Updates to the Alberta Drug Benefit List. Effective October 1, 2017
Updates to the Alberta Drug Benefit List Effective October 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Updates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective October 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
NBPDP Formulary Update
Bulletin # 853 January 31, 2013 NBPDP Formulary Update Please find attached lists of interchangeable product additions to the New Brunswick Prescription Drug Program Formulary and non-listed products subject
BULLETIN # 72. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on April 18, 2013
BULLETIN # 72 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on April 18, 2013 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN FOR THE UPDATE TO THE 56th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch January 2007 Bulletin #109 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN FOR THE UPDATE TO THE 56th EDITION OF THE SASKATCHEWAN FORMULARY
BULLETIN # 78. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2014
BULLETIN # 78 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on July 17, 2014 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Non-Insured Health Benefits
Fall 2016 Non-Insured Health Benefits First Nations and Inuit Health Branch Updates to the Drug Benefit List The Non-Insured Health Benefits (NIHB) Program provides supplementary health benefits, including
Ontario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - April 2015 Effective April 30, 2015 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
SASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health July 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #124 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
Updates to the Alberta Health and Wellness Drug Benefit List
Updates to the Alberta Health and Wellness Drug Benefit List Effective May 1, 2012 UPDATES TO THE ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Inquiries should be directed to: Pharmacy Services Alberta
Bosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
BULLETIN # 90. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 25, 2017
BULLETIN # 90 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on January 25, 2017 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Updates to the Alberta Drug Benefit List. Effective September 1, 2018
Updates to the Alberta Drug Benefit List Effective September 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Updates to the Alberta Drug Benefit List. Effective May 1, 2018
Updates to the Alberta Drug Benefit List Effective May 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
Updates to the Alberta Drug Benefit List. Effective July 1, 2018
Updates to the Alberta Drug Benefit List Effective July 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
Prescriber Validation
FEBRUARY 03 VOLUME 3-0 PHARMACISTS EDITION Nova Scotia Formulary Updates Nova Scotia Formulary Updates Prescriber Validation www.medavie.bluecross.ca\healthprofessionals PAGE OF 5 PHARMACISTS EDITION VOLUME
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION
Saskatchewan Health Drug Plan and Extended Benefits Branch January 2005 Bulletin #101 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION NEW FULL FORMULARY LISTING: The
CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
Updates to the Alberta Drug Benefit List. Effective June 1, 2018
Updates to the Alberta Drug Benefit List Effective June 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
Updates to the Alberta Drug Benefit List. Effective December 1, 2018
Updates to the Alberta Drug Benefit List Effective December 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
20:00. Blood Formulation, Coagulation and Thrombosis. 20:00 Blood Formulation, Coagulation and Thrombosis
Blood Formulation, Coagulation and Thrombosis Blood Formulation, Coagulation and Thrombosis 20:04.04 ANTIANEMIA DRUGS (IRON PREPARATIONS) IRON DEXTRAN COMPLEX 50 MG / ML INJECTION 00002205963 DEXIRON LPI
UPDATE Z Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 04, 2011 SUMMARY OF CHANGES
UPDATE Z Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 04, 2011 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 4 Off Formulary
BULLETIN # 101. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 18, 2018
BULLETIN # 101 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 18, 2018 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
BULLETIN # 99. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 19, 2018
BULLETIN # 99 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on July 19, 2018 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN 55th EDITION
Saskatchewan Health Drug Plan and Extended Benefits Branch July 2005 Bulletin #103 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN 55th EDITION All listings are effective July 1, 2005 NEW FULL
P.E.I. Pharmacare Formulary
\ P.E.I. Pharmacare Formulary PEI Pharmacare Formulary Page - 1 - Inquiries should be directed to: PEI Pharmacare Health PEI P.O. Box 2000, 20 Fitzroy St. Charlottetown, PEI C1A 7N8 Telephone inquiries
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
BULLETIN # 65. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 14, 2010.
BULLETIN # 65 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 14, 2010. The amended Manitoba Specified Drug Regulation and Drug Interchangeability
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
BULLETIN # 50. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on March 13, 2006.
BULLETIN # 50 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on March 13, 2006. The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Updates to the Alberta Drug Benefit List. Effective August 1, 2017
Updates to the Alberta Drug Benefit List Effective August 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch July 2008 Bulletin #115 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY